{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:18:47Z","timestamp":1783354727578,"version":"3.54.6"},"reference-count":32,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,12,9]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preventing acute exacerbations in COPD (AECOPDs) is key in striving for disease stability. To investigate the differential impact of risk factors across AECOPD phenotypes, we identified baseline health determinants and comorbidities associated with transitions from non-exacerbator (NE) to persistent frequent-exacerbator (FE) and reversion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients \u226545\u2005years with \u22653\u2005months treatment for obstructive airway diseases or hospital-labelled COPD without (concomitant) asthma were identified in Belgian nationwide data between January 2017\u2013February 2018. Factors associated with disease worsening (transitioning from NE to persistent FE), reversion (from FE to stable NE) or transition to death were investigated using multinomial logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 183\u2009762 patients (mean age 68.6\u2005years, 48.0% female), 11.5% (21\u2009072) never experienced AECOPDs and 11.6% (21\u2009375) exacerbated frequently in each of three consecutive years. Among 56\u2009933 NE at baseline (31.0%), 4.1% transitioned to persistent FE, whereas among 80\u2009502 FE (43.8%), 7.3% reversed to stable NE. Transitions from NE towards persistent FE were associated with having lung cancer (adjusted odds ratio (aOR) 3.67, 95% CI 2.33\u20135.78), being an ever-smoker (aOR 2.09, 95% CI 1.94\u20132.43) or having neuropsychiatric or musculoskeletal comorbidity. Overuse of short-acting bronchodilators (aOR 0.57, 95% CI 0.46\u20130.49), ever-smoking or having overuse of maintenance therapy were factors most strongly associated with lower odds of reversion. Cardiovascular comorbidities were significantly associated with increased mortality odds, but not with disease worsening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this cohort study support addressing smoking and inhaler overuse to promote reversion to stable NE, while managing lung cancer and neuropsychiatric or musculoskeletal comorbidities to reduce worsening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01098-2025","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:35:18Z","timestamp":1769776518000},"page":"01098-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Transitions to and reversion from a persistent frequent-exacerbator state in COPD"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-476X","authenticated-orcid":false,"given":"Delphine","family":"Vauterin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-7651","authenticated-orcid":false,"given":"Frauke","family":"Van Vaerenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-4096","authenticated-orcid":false,"given":"Lowie E.G.W.","family":"Vanfleteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-4363","authenticated-orcid":false,"given":"Lies","family":"Lahousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026070608550672000_12.3.01098-2025.1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global strategy for prevention, diagnosis and management of COPD: 2025 Report. 2025."},{"key":"2026070608550672000_12.3.01098-2025.2","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1007\/s12325-024-02982-y","article-title":"Striving for stability in patients with COPD: a new way forward?","volume":"41","author":"Han","year":"2024","journal-title":"Adv Ther"},{"key":"2026070608550672000_12.3.01098-2025.3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1164\/rccm.202406-1254CI","article-title":"Is disease stability an attainable COPD treatment goal?","volume":"211","author":"Singh","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026070608550672000_12.3.01098-2025.4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2213-2600(21)00227-7","article-title":"Research priorities for exacerbations of COPD","volume":"9","author":"Alqahtani","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026070608550672000_12.3.01098-2025.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201106-1136ED"},{"key":"2026070608550672000_12.3.01098-2025.6","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.3390\/jcm14093132","article-title":"Phenotypes of exacerbations in chronic obstructive pulmonary disease","volume":"14","author":"Nisip Avram","year":"2025","journal-title":"J Clin Med"},{"key":"2026070608550672000_12.3.01098-2025.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909883"},{"key":"2026070608550672000_12.3.01098-2025.8","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-181"},{"key":"2026070608550672000_12.3.01098-2025.9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.chest.2017.10.009","article-title":"Defining the \u201cfrequent exacerbator\u201d phenotype in COPD: a hypothesis-free approach","volume":"153","author":"Le Rouzic","year":"2018","journal-title":"Chest"},{"key":"2026070608550672000_12.3.01098-2025.10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12931-022-02123-5","article-title":"Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review","volume":"23","author":"Hurst","year":"2022","journal-title":"Respir Res"},{"key":"2026070608550672000_12.3.01098-2025.11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00408-022-00565-8","article-title":"Trajectories of severe exacerbations of chronic obstructive pulmonary disease and their relationship with mortality risk","volume":"200","author":"Golpe","year":"2022","journal-title":"Lung"},{"key":"2026070608550672000_12.3.01098-2025.12","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-14-79"},{"key":"2026070608550672000_12.3.01098-2025.13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/resp.14222","article-title":"The HUNT study: association of comorbidity clusters with long-term survival and incidence of exacerbation in a population-based Norwegian COPD cohort","volume":"27","author":"Vikjord","year":"2022","journal-title":"Respirology"},{"key":"2026070608550672000_12.3.01098-2025.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"2026070608550672000_12.3.01098-2025.15","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.01276-2024"},{"key":"2026070608550672000_12.3.01098-2025.16","unstructured":"InterMutualistic Agency (IMA\/AIM) . Health data. 2024. Date last updated: 24 September 2024. Date last accessed: 7 October 2024. https:\/\/ima-aim.be\/"},{"key":"2026070608550672000_12.3.01098-2025.17","unstructured":"The Minimal Hospital Dataset . Minimale Ziekenhuis Gegevens (MZG). 2024. Date last updated: 2 July 2024. Date last accessed: 7 October 2024. https:\/\/www.health.belgium.be\/en\/professionals\/health-professionals\/human-health\/data-management\/data-registration-healthcare-facilities\/minimal-hospital-data-mhd"},{"key":"2026070608550672000_12.3.01098-2025.18","unstructured":"The Sectoral Committee of Social Security and Health, Section Health. Information Security Committee. 2024. Date last updated: 27 May 2024. Date last accessed: 7 October 2024. www.ehealth.fgov.be\/ehealthplatform\/nl\/informatieveiligheidscomite"},{"key":"2026070608550672000_12.3.01098-2025.19","unstructured":"Belgian Antibiotic Policy Coordination Commission (BAPCOC) . Belgische gids voor anti-infectieuze behandeling in de ambulante praktijk. 2012. Date last updated: 7 May 2013. Date last accessed: 22 May 2024. www.bcfi.be\/legacy_assets\/antibioticagids-nl.pdf"},{"key":"2026070608550672000_12.3.01098-2025.20","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00722-2022"},{"key":"2026070608550672000_12.3.01098-2025.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201209-1665OC"},{"key":"2026070608550672000_12.3.01098-2025.22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S2213-2600(23)00261-8","article-title":"COPD and multimorbidity: recognising and addressing a syndemic occurrence","volume":"11","author":"Fabbri","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026070608550672000_12.3.01098-2025.23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pupt.2018.09.001","article-title":"Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study","volume":"53","author":"Scalone","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"2026070608550672000_12.3.01098-2025.24","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092614"},{"key":"2026070608550672000_12.3.01098-2025.25","unstructured":"Desimpel F , Luyten J , Camberlin C , et al. Federaal Kenniscentrum voor de Gezondheidszorg (KCE). - Longkankerscreening bij personen met een hoog risico. Health Technology Assessment (HTA) - KCE Reports 379AS. Brussel; 2024."},{"key":"2026070608550672000_12.3.01098-2025.26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.rmed.2014.12.006","article-title":"Characterisation of the frequent exacerbator phenotype in COPD patients in a large UK primary care population","volume":"109","author":"McGarvey","year":"2015","journal-title":"Respir Med"},{"key":"2026070608550672000_12.3.01098-2025.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006171"},{"key":"2026070608550672000_12.3.01098-2025.28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12931-017-0512-2","article-title":"Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD","volume":"18","author":"Westerik","year":"2017","journal-title":"Respir Res"},{"key":"2026070608550672000_12.3.01098-2025.29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2147\/COPD.S85363","article-title":"Clinical characteristics of the asthma-COPD overlap syndrome - a systematic review","volume":"10","author":"Ulrik","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026070608550672000_12.3.01098-2025.30","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00128008"},{"key":"2026070608550672000_12.3.01098-2025.31","doi-asserted-by":"crossref","first-page":"100249","DOI":"10.1016\/j.opresp.2023.100249","article-title":"The relevance of comorbidities in the persistence of exacerbations in patients with chronic obstructive pulmonary disease","volume":"5","author":"Figueira-Gon\u00e7alves","year":"2023","journal-title":"Open Respir Arch"},{"key":"2026070608550672000_12.3.01098-2025.32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.rmed.2019.10.007","article-title":"Higher short-acting beta-agonist use is associated with greater COPD burden","volume":"158","author":"Gondalia","year":"2019","journal-title":"Respir Med"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01098-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:55:34Z","timestamp":1783353334000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01098-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1183\/23120541.01098-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01098-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}